DDInter856 DDInter200
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients .
Betrixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Betrixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amprenavir
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Berotralstat
Betrixaban {u} may lead to a major life threatening interaction when taken with {v} Iloprost
Betrixaban {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Betrixaban may cause a minor interaction that can limit clinical effects when taken with Clove
Betrixaban may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Betrixaban may lead to a major life threatening interaction when taken with Iloprost
Betrixaban may lead to a major life threatening interaction when taken with Avapritinib